NONINVASIVE PROTEOMIC BIOMARKER IN DISORDERS OF THE NONALCOHOLIC FATTY LIVER

Fatty liver disease that is not alcoholic, often known as non-alcoholic fatty liver disease, is a common and progressive liver ailment that is defined by an abnormal buildup of fat in the liver when significant alcohol use is avoided.
Nonalcoholic fatty liver disease is a frequent and progressive liver disorder. A variety of conditions are referred to as nonalcoholic fatty liver disease, which might include nonalcoholic steatohepatitis and simple steatosis. which can eventually lead to cirrhosis and hepatocellular cancer. Among nonalcoholic fatty liver disease, simple steatosis is the most prevalent kind. Even though it is invasive and has various drawbacks, liver biopsy is still considered the gold standard for diagnosing and staging nonalcoholic fatty
liver disease at the present time. As a result, there is an immediate need for noninvasive biomarkers that are capable of providing an accurate diagnosis, staging, and monitoring of the development of illness.
In recent years, proteomic methods have emerged as potentially useful tools for the identification and validation of noninvasive biomarkers in nonalcoholic fatty liver disease. This development has place over the course of many years.
The objective of this research study is to provide an overview of the existing situation of noninvasive proteomic biomarkers in nonalcoholic fatty liver disease as well as their possible implications in clinical practice.